145 related articles for article (PubMed ID: 24867249)
1. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Bai XL; Zhang Q; Ye LY; Hu QD; Fu QH; Zhi X; Su W; Su RG; Ma T; Chen W; Xie SZ; Chen CL; Liang TB
Mol Cancer Ther; 2014 Aug; 13(8):2062-72. PubMed ID: 24867249
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis.
Bai X; Zhi X; Zhang Q; Liang F; Chen W; Liang C; Hu Q; Sun X; Zhuang Z; Liang T
Cancer Lett; 2014 Dec; 355(2):281-7. PubMed ID: 25304380
[TBL] [Abstract][Full Text] [Related]
3. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
[TBL] [Abstract][Full Text] [Related]
4. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
5. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
[TBL] [Abstract][Full Text] [Related]
6. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Ho WS; Sizdahkhani S; Hao S; Song H; Seldomridge A; Tandle A; Maric D; Kramp T; Lu R; Heiss JD; Camphausen K; Gilbert MR; Zhuang Z; Park DM
Cancer Lett; 2018 Feb; 415():217-226. PubMed ID: 29199006
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.
Chen T; Yuan SJ; Wang J; Hu W
World J Gastroenterol; 2015 Sep; 21(35):10126-36. PubMed ID: 26401077
[TBL] [Abstract][Full Text] [Related]
9. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
[TBL] [Abstract][Full Text] [Related]
11. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Zhu DW; Yuan YX; Qiao JK; Yu C; Yang X; Wang LZ; Zhang ZY; Zhong LP
Cancer Lett; 2015 Jan; 356(2 Pt B):773-80. PubMed ID: 25449438
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Zhu XD; Zhang JB; Fan PL; Xiong YQ; Zhuang PY; Zhang W; Xu HX; Gao DM; Kong LQ; Wang L; Wu WZ; Tang ZY; Ding H; Sun HC
BMC Cancer; 2011 Jan; 11():28. PubMed ID: 21251271
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
17. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
Jia WD; Xu GL; Xu RN; Sun HC; Wang L; Yu JH; Wang J; Li JS; Zhai ZM; Xue Q
J Cancer Res Clin Oncol; 2003 Jun; 129(6):327-34. PubMed ID: 12811549
[TBL] [Abstract][Full Text] [Related]
18. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
[TBL] [Abstract][Full Text] [Related]
20. Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
World J Gastroenterol; 2007 Apr; 13(13):1989-94. PubMed ID: 17461503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
